Ukraine Issues First Medical Cannabis Prescriptions Since Legalizing

Ukraine’s medical cannabis program moved from statute to bedside this week, as a war veteran and a multiple sclerosis patient became the first people in the country to receive legal cannabis-based prescriptions — nearly two years after the authorizing law took effect.

On June 11, 2026, neurologists at the Vinnytsia Regional Clinical Psychoneurological Hospital prescribed cannabis medicine to Lyudmila Monastyrska, who has multiple sclerosis, and Yaroslav Yurchuk, a veteran who lost a leg about a year ago in fighting near Pokrovsk. According to the Ukrainian Medical Cannabis Association and the treating physicians, both patients received a THC capsule — the first prescriptions written under a framework Ukraine’s parliament approved in December 2023.

A two-year gap between law and access

Ukraine moved to legalize medical cannabis largely as a wartime health measure, aimed at veterans and seriously ill patients, with the Ministry of Health estimating that roughly six million citizens could eventually qualify for treatment. President Volodymyr Zelensky signed the legislation in February 2024, and it formally took effect on August 16, 2024. That much had been on the public record since the country first legalized cannabis for medical use.

A law on the books, though, is not medicine on a shelf. The 22-month delay between the law taking effect and the first prescription is the gap that defines transitional markets: before a controlled-substance program can run, a government has to register products, license the supply chain, write pharmacy-compounding rules, and stand up a tracking system. Each of those steps took time in a country still under daily Russian attack.

The first products reached Ukraine’s State Register of Medicinal Products in January 2025 — three oil-based products registered by Curaleaf International, the first company into the market. Even registration did not flip a switch. Pharmacies that want to dispense need three separate licenses — for retail trade, drug manufacturing, and narcotics handling — which industry estimates put at roughly 200 eligible outlets nationwide. Ukraine also uses a magistral model, meaning those pharmacies compound the medicine in-house rather than selling finished packs off the shelf.

What the program covers — and what it leaves out

The Health Ministry’s list of qualifying conditions covers multiple sclerosis, chronic and neuropathic pain, spasticity, Parkinson’s disease, treatment-resistant epilepsy, chemotherapy-induced nausea, and several childhood seizure disorders. One condition is conspicuously absent: post-traumatic stress disorder.

That omission matters because the law was promoted, in part, as relief for soldiers coming home from the front — and PTSD is among the most common wartime diagnoses. Patient organizations, including Patients of Ukraine, have argued that the current list is too narrow and pressed for PTSD to be added. The first veteran to receive a prescription qualified on the basis of a physical injury, not psychological trauma — a reminder that the program’s stated purpose and its operational scope do not yet fully overlap. In the United States, by contrast, federal researchers have moved to study psychedelic therapy for veterans with PTSD, a population Ukraine’s cannabis framework so far excludes.

Imports now, domestic supply later

For operators weighing the market, Ukraine will run on imports for the foreseeable future. The law holds the import quota for cannabis plants and raw substances at zero until 2028, routing early supply through registered finished medicines and active ingredients — the lane Curaleaf used to enter first. Import permits are issued within annual limits by the State Service of Ukraine on Medicines and Drug Control, and in late 2025, the government set its first quotas covering medical cannabis substances, including THC, for 2026.

Domestic production is being built in parallel. Complant Consulting, a firm working with regulators and manufacturers on Ukraine’s supply chain, has said local cultivation could come online before 2028, with the first facilities already under construction. The Ukrainian Medical Cannabis Association, which has campaigned for legal access since 2018, has framed the first prescriptions as a starting point rather than a finish line, with domestic cultivation the next milestone. Every stage from seed to pharmacy is meant to be traceable through an electronic system the Health Ministry built into its eHealth platform (EHTH ), and prescriptions are issued electronically only — a control regime tighter than most of the European markets that U.S. and multinational operators are eyeing for expansion.

Two prescriptions in Vinnytsia are a small number against the millions the Health Ministry says could benefit, and against the European cannabis markets now drawing the most investor attention. But in a transitional market, the line between an aspirational law and a working program is exactly this: the day a patient walks out of a pharmacy with the medicine. The questions that follow are operational ones — how quickly the eligible pharmacies come online, whether PTSD joins the qualifying list, and when Ukrainian cultivation can take over from imports.